Lev Kats

Clonal multi-omics reveals Bcor as a negative regulator of emergency dendritic cell development

Luyi Tian, Sara Tomei, Jaring Schreuder, Tom S Weber, Daniela Amann-Zalcenstein, Dawn S Lin, Jessica Tran, Cindy Audiger, Mathew Chu, Andrew Jarratt, Tracy Willson, Adrienne Hilton, Ee Shan Pang, Timothy Patton, Madison Kelly, Shian Su, Quentin Gouil, Peter Diakumis, Melanie Bahlo, Toby Sargeant, et al.

Journal article  |  2021  |  IMMUNITY

Despite advances in single-cell multi-omics, a single stem or progenitor cell can only be tested once. We developed clonal multi-o..

Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD-Driven Acute Myeloid Leukemia

Stefan Bjelosevic, Emily Gruber, Andrea Newbold, Carolyn Shembrey, Jennifer R Devlin, Simon J Hogg, Lev Kats, Izabela Todorovski, Zheng Fan, Thomas C Abrehart, Giovanna Pomilio, Andrew Wei, Gareth P Gregory, Stephin J Vervoort, Kristin K Brown, Ricky W Johnstone

Journal article  |  2021  |  CANCER DISCOVERY

Internal tandem duplication of the FMS-like tyrosine kinase 3 gene (FLT3-ITD) occurs in 30% of all acute myeloid leukemias (AML). ..

CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy

Lauren Giuffrida, Kevin Sek, Melissa A Henderson, Junyun Lai, Amanda XY Chen, Deborah Meyran, Kirsten L Todd, Emma Petley, Sherly Mardiana, Christina Molck, Gregory D Stewart, Benjamin J Solomon, Ian A Parish, Paul J Neeson, Simon J Harrison, Lev M Kats, Imran G House, Phillip K Darcy, Paul A Beavis

Journal article  |  2021  |  NATURE COMMUNICATIONS

Adenosine is an immunosuppressive factor that limits anti-tumor immunity through the suppression of multiple immune subsets includ..

Pulling the Pin on NPMc acute myeloid leukemia.

Lev M Kats

Journal article  |  2021  |  Haematologica

Not available.

Non-genetic heterogeneity, altered cell fate and differentiation therapy

Alexander C Lewis, Lev M Kats

Journal article  |  2021  |  EMBO MOLECULAR MEDICINE

Altered capacity for self-renewal and differentiation is a hallmark of cancer, and many tumors are composed of cells with a develo..

IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors

Lauren Giuffrida, Kevin Sek, Melissa A Henderson, Imran G House, Junyun Lai, Amanda XY Chen, Kirsten L Todd, Emma Petley, Sherly Mardiana, Izabela Todorovski, Emily Gruber, Madison J Kelly, Benjamin J Solomon, Stephin J Vervoort, Ricky W Johnstone, Ian A Parish, Paul J Neeson, Lev M Kats, Phillip K Darcy, Paul A Beavis

Journal article  |  2020  |  MOLECULAR THERAPY

Chimeric antigen receptor (CAR) T cell therapy has been highly successful in hematological malignancies leading to their US Food a..

Epigenetic reprogramming of plasmacytoid dendritic cells drives type I interferon-dependent differentiation of acute myeloid leukemias for therapeutic benefit

Jessica Salmon, Izabela Todorovski, Stephin Vervoort, Kym Stanley, Conor Kearney, Luciano Martelotto, Fernando Rossello, Tim Semple, Gisela Mir-Arnau, Magnus Zethoven, Michael Bots, Eva Vidacs, Kate McArthur, Elise Gressier, Nicky de Weerd, Jens Lichte, Madison Kelly, Leonie Cluse, Simon Hogg, Paul Hertzog, et al.

Journal article  |  2020

Pharmacological inhibition of epigenetic enzymes can have therapeutic benefit, particularly against hematological malignancies. Wh..

Pharmacological and genetic strategies for targeting adenosine to enhance adoptive T cell therapy of cancer

Kevin Sek, Lev M Kats, Phillip K Darcy, Paul A Beavis

Journal article  |  2020  |  CURRENT OPINION IN PHARMACOLOGY

Adoptive cellular therapy involves the ex vivo expansion of immune cells, conventionally T cells, before reinfusion back to the pa..

Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia

Emily Gruber, Rheana L Franich, Jake Shortt, Ricky W Johnstone, Lev M Kats

Journal article  |  2020  |  LEUKEMIA

Reprogramming of serine metabolism is an actionable vulnerability in FLT3-ITD driven acute myeloid leukaemia

Stefan Bjelosevic, Emily Gruber, Andrea Newbold, Lev Kats, Carolyn Shembrey, Thomas Abrehart, Izabela Todorovski, Giovanna Pomilio, Andrew Wei, Gareth Gregory, Stephin Vervoort, Kristin Brown, Ricky Johnstone

Journal article  |  2020

Activating FMS-like tyrosine kinase 3 ( FLT3 ) mutations occur in approximately 30% of all acute myeloid leukaemias (AMLs) and are..